Kliniske studier for Lymfom i Minnesota
14 studier for Lymfom søker deltakere på steder i Minnesota.
Byer i Minnesota
Offisiell studietekst (engelsk)
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Mayo Clinic Health Systems-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT03418038CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- University of Minnesota/Masonic Cancer Center, Minneapolis
RekruttererFase 1/2
12 Months – 21 Years · Alle kjønn · Oppdatert 11. sep. 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Rochester
RekruttererFase 3
Alder 18 til 18 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07509151Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT04588922Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Rochester, Rochester
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT04792489Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
RekruttererFase 2
Opp til 60 år · Alle kjønn · Oppdatert 25. jun. 2026 · NCT03314974CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Mayo Clinic, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. apr. 2026 · NCT03328078Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
- Mayo Clinic in Rochester, Rochester
RekruttererTidlig fase 1Frivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 16. mar. 2026 · NCT05294367BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Mayo Clinic, Rochester
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. feb. 2026 · NCT06854003cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Allina Health Cancer Institute, Minneapolis
- Mayo Clinic, Rochester
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366881Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- Fairview Southdale Hospital, Edina
- Hennepin County Medical Center, Minneapolis
- Monticello Cancer Center, Monticello
- og 5 flere
RekruttererFase 3Frivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jan. 2026 · NCT05006482WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
- Mayo Clinic in Rochester, Rochester
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 15. okt. 2025 · NCT07058064Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.